In
fact, until now, no therapy has been developed to stop or at least slow down the
neurodegeneration occurring in dopaminergic neurons in PD patients. Levodopa (3,4-dihydroxy-l-phenylalanine, L-DOPA) is a precursor of DA and
it represents the first and most successful breakthrough in the symptomatic treat-
ment of PD. In fact, DA replacement therapy with L-DOPA is still the gold
standard for symptomatic treatment of PD. However, patients usually experience

THE ROYAL SOCIETY

PUBLISHING Â© 2015 The Author(s) Published by the Royal Society. All rights reserved.


motor and behavioural effects mechanisms of action

increase of
DA release

motor cognitive
activation activity

synaptic plasticity

stimulate

Wat

NMDAR subunit
changes

dyskinesia

ey

increase in
BDNF

sprouting of
5-HT fibres

impulse control disorders

Figure 1.